EUPRAXIA PHARMACEUTICALS INC.

Eupraxia Pharmaceuticals announced significant changes to its executive leadership team to support its next phase of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, bringing extensive experience in CMC and regulatory strategy. Dr. Alex Therien will now lead Research & Development as Executive Vice President, R&D. Additionally, Amanda Malone stepped down from her role, and the company is transitioning its operations to Vancouver and Seattle, with key executives based in Seattle.

Eupraxia Pharmaceuticals Inc. announced the appointment of three new industry leaders, Robert Bazemore, Amy Pott, and Dr. Helen Thackray, to its Board of Directors. These appointments are expected to strengthen the company's expertise in late-stage drug development, commercial strategy, and global product launches, particularly as it advances its EP-104GI program and expands its pipeline. The company also acknowledged the departure of long-serving directors Paul Geyer and Michael Wilmink.

Eupraxia Pharmaceuticals announced the results of its Annual General Meeting of Shareholders held on June 18, 2026. Shareholders approved the election of all seven management-proposed nominees to the Board of Directors. Additionally, KPMG LLP was re-appointed as the company's auditor for the upcoming year, and shareholders authorized the Board to fix the auditors' remuneration. All items of business presented at the meeting were passed with strong shareholder support.

Eupraxia Pharmaceuticals Inc. announced the results of its Annual General Meeting held on June 18, 2026. All seven nominees proposed by management for election to the Company's board of directors were successfully elected. Additionally, shareholders re-appointed KPMG LLP as the auditor for the upcoming year and authorized the Board to determine their remuneration. All items of business presented at the meeting were passed by the shareholders.

Eupraxia Pharmaceuticals Inc. announced its Annual General Meeting (AGM) of shareholders will be held virtually on June 18, 2026. Key items on the agenda include receiving and considering the audited financial statements for 2025 and 2024, setting the number of directors at seven, electing directors, and appointing KPMG LLP as the auditor. Shareholders of record as of May 8, 2026, are entitled to vote, with a proxy submission deadline of June 16, 2026.

Eupraxia Pharmaceuticals Inc. announced the mailing of proxy-related materials on May 27, 2026. These materials were sent to both Registered Securityholders and ESP Holders in preparation for an upcoming meeting. The package included a Proxy with Request for Financial Statements, a Voting Instruction Form, a Notice of Meeting combined with an Information Circular, and a Proxy Return Envelope.

Eupraxia Pharmaceuticals Inc. announced its management team will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026. The presentation is scheduled from 5:30 PM to 6:00 PM ET in New York, NY. The company will also be available for 1x1 meetings on June 3rd and 4th.

Eupraxia Pharmaceuticals reported a net loss of $(12.65) million for Q1 2026, compared to $(6.77) million in Q1 2025. The company successfully completed a public offering, raising $63.2 million in gross proceeds. As of March 31, 2026, Eupraxia held $58.50 million in cash and cash equivalents and $80.38 million in short-term investments, providing a total of $138.88 million in liquidity. This capital is expected to fund operations into H2 2028, supporting further development of EP-104GI, which showed positive tissue health data in the RESOLVE trial for Eosinophilic Esophagitis.

Eupraxia Pharmaceuticals announced its Q1 2026 financial results, reporting a net loss of $12.7 million. The company successfully completed a $63.2 million public offering, issuing 7,607,145 common shares and 1,428,571 pre-funded warrants. This financing, combined with existing cash, provides over $140 million in cash and short-term investments, extending its runway into H2 2028. Additionally, clinical data for EP-104GI in Eosinophilic Esophagitis (EoE) from the RESOLVE trial demonstrated robust tissue health and symptom improvement after 36 weeks.

Eupraxia Pharmaceuticals announced the first release of EoEHSS sub score data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis (EoE). The data, presented at Digestive Disease Week, showed improvements in both inflammatory (EoEHSS-i) and architectural/fibrotic (EoEHSS-a) sub scores across most cohorts at 12 and 36 weeks. The highest dose cohort (cohort 9) demonstrated the largest improvements, with over 90% in inflammation and over 83% in tissue architecture, consistent with previous symptom and endoscope scoring data.